The present multicenter real-world study of treatment outcomes in patients with NSCLC harboring rare genetic alterations, i.e., BRAF and cMET exon 14 skipping mutations, has clearly shown the benefit of using targeted therapies, preferably in the first-line setting. The gene discussed is BRAF; the disease is non-small cell lung carcinoma.